UCB : Bimekizumab sur de bons rails
>Bimekizumab : CHMP positif dans le psoriasis - Le cours d’UCB progressait de +3% vendredi dernier (après une suspension momentanée du cours) à la suite d’une recommandation positive du Comité des médicaments à usage humain (CHMP) de l’EMA pour bimekizumab dans le traitement du psoriasis en plaques modéré à sévère. Nous ne voyons pas ce verdict comme une surprise mais plutôt comme la confirmation de notre opinion sur son développement clinique. Pour rappel, les résul...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.